Home›Trial›NCT05032976
NCT05032976ACTIVE NOT RECRUITING

Korea Comirnaty Post-marketing Surveillance

Study Summary

This study will collect information on the safety of BNT162b2 products for subjects who have been administered in a routine clinical practice from 05Mar2021 to 04Mar2027 in Korea, and will be conducted in accordance with the New Drug Re-Examination Guideline of the Ministry of Food and Drug Safety (MFDS).

Conditions
COVID-19VaccinesAdverse EffectsSARS-CoV-2Safety
Interventions / Drugs
Tozinameran 12 Years of age and olderTozinameran 5 to 11 Years of ageTozinameran 6 months to 4 years of ageRiltozinameran 12 Years of age and olderFamtozinameran 12 Years of age and olderFamtozinameran 5 to 11 Years of ageRaxtozinameran 12 years of age and olderRaxtozinameran 6 months to 4 years of age
View on ClinicalTrials.gov ↗
Sponsor
PFE
Pfizer Inc
Diversified Pharma
F33/100
Study Details
Enrollment12000 participants
Primary Completion—
Lead SponsorPfizer
Data Retrieved2026-04-11 02:55:53.189666+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 12,000 participants
Sponsor Catalyst Profile

Pfizer Inc (PFE) is the sponsoring company for this trial. BiotechSign currently grades this company F (33/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

PFE Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.